Friday, 16 October 2026European Markets

GOLDEN OCEAN GROUP And STOLT-NIELSEN Have A High Dividend Yield And Return On Equity In The Marine Shipping Industry.

Loading stream...

(VIANEWS) - GOLDEN OCEAN GROUP (GOGL.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Marine Shipping industry.

Financial Asset Price Forward Dividend Yield Return on Equity
GOLDEN OCEAN GROUP (GOGL.OL) kr78.56 17.12% 17.52%
STOLT-NIELSEN (SNI.OL) kr266.50 10.49% 16.61%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. GOLDEN OCEAN GROUP (GOGL.OL)

17.12% Forward Dividend Yield and 17.52% Return On Equity

Golden Ocean Group Limited, a shipping company, owns and operates a fleet of dry bulk vessels worldwide. It operates dry bulk vessels comprising of Newcastlemax, Capesize, Panamax, and Ultramax vessels in the spot and time charter markets. The company's vessels transport a range of bulk commodities, such as ores, coal, grains, and fertilizers. As of March 16, 2023, it owned a fleet of 74 dry bulk vessels. The company is based in Hamilton, Bermuda.

Earnings Per Share

As for profitability, GOLDEN OCEAN GROUP has a trailing twelve months EPS of kr17.42.

PE Ratio

GOLDEN OCEAN GROUP has a trailing twelve months price to earnings ratio of 4.51. Meaning, the purchaser of the share is investing kr4.51 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.52%.

More news about GOLDEN OCEAN GROUP.

2. STOLT-NIELSEN (SNI.OL)

10.49% Forward Dividend Yield and 16.61% Return On Equity

Stolt-Nielsen Limited provides transportation, storage, and distribution solutions for bulk liquid chemicals, edible oils, acids, and other specialty liquids worldwide. It operates through five segments: Tankers, Terminals, Tank Containers, Stolt Sea Farm, and Stolt-Nielsen Gas. The company also produces, processes, and markets seafood, including turbot and sole; and transports, stores, and distributes chemicals, clean petroleum products, liquefied petroleum gases, vegetable oils, biofuels, and oleochemicals, as well as alternative fuels and feedstocks. In addition, it owns and operates liquid natural gas carriers. The company was founded in 1959 and is based in London, the United Kingdom. Stolt-Nielsen Limited is a subsidiary of Fiducia Ltd.

Earnings Per Share

As for profitability, STOLT-NIELSEN has a trailing twelve months EPS of kr55.55.

PE Ratio

STOLT-NIELSEN has a trailing twelve months price to earnings ratio of 4.8. Meaning, the purchaser of the share is investing kr4.8 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.61%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, STOLT-NIELSEN's stock is considered to be oversold (<=20).

More news about STOLT-NIELSEN.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com